Bayesian approach enabled objective comparison of multiple human iPSC-derived Cardiomyocytes' Proarrhythmia...

Area of Science:

• Cardiovascular Pharmacology
• Drug Safety Assessment
• Stem Cell Technology

Background:

• Traditional medicine uses a one-size-fits-all approach, while precision medicine targets specific patient groups.
• Computational modeling aids drug-induced proarrhythmia risk prediction in silico.
• Population modeling in experimental safety pharmacology presents challenges.

Purpose of the Study:

• To develop and validate novel methods for assessing compound-induced proarrhythmia risks in human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs).
• To characterize and compare the proarrhythmic sensitivities of different hiPSC-CM cell lines to various compounds.
• To integrate phenotypic data with ion channel inhibition for objective drug safety evaluation.

Main Methods:

• Utilized five human iPSC-CM cell lines in 384-well plates to test ten proarrhythmic compounds at four concentrations.
• Analyzed calcium transients (CaTs) and defined six parameters to characterize waveform changes and beat irregularities.
• Employed Bayesian statistics for population prediction and principal component analysis for objective classification of compound-induced sensitivities.

Main Results:

• All cell lines showed compound-dependent alterations in CaT duration, with some exhibiting irregular beating not predicted by simulations.
• Novel parameters effectively visualized and differentiated compound-induced proarrhythmic sensitivities across cell lines.
• Bayesian statistics and principal component analysis enabled objective classification of cell line sensitivities.

Conclusions:

• The developed phenotypic parameters and statistical approaches provide a robust method for assessing drug-induced proarrhythmia risk in hiPSC-CMs.
• This approach overcomes limitations of experimental replicates in high-throughput assays and aids in objective drug safety evaluation.
• The findings contribute to advancing personalized medicine and improving the prediction of drug-induced cardiac adverse events.